
Scibase Q3'2024 - Financing to accelerate US

Redeye saw a Q3 report in which sales and gross margins slightly exceeded our estimates. The highlights in connection with the report are the proposed rights and directed issues aimed to bring in c SEK 82m before costs. We have trimmed our estimates downward for 2025e, although the significant difference in our fair value range is the expected new number of shares. We lower our fair value range to SEK 0.5-3.5 and our Base case to SEK 1.6(2.8) per share.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Scibase Q3'2024 - Financing to accelerate US](#)